Squarex has developed a topical formulation (SQX770) for prevention of recurrent cold sores (herpes labialis) an other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.
SQX770 is the only product shown to reduce the number of cold sore events or flareups as well as their severity.
The company is now accepting investments.
To learn more about this investment opportunity, please email our CFO
Joe Cunningham at: firstname.lastname@example.org
CEO / President and Chief Scientist of Squarex